In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Persistence of impaired chronotropic responses after the completion of phase II cardiac rehabilitation predicts a poor long-term cardiovascular prognosis

Session Poster session 4

Speaker Mariko Ehara

Congress : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Poster Session
  • FP Number : P3425

Authors : M Ehara (Nagoya,JP), K Shibata (Nagoya,JP), M Kameshima (Nagoya,JP), M Konaka (Nagoya,JP), H Fujiyama (Nagoya,JP), M Kato (Nagoya,JP), Y Higashida (Nagoya,JP), A Shimada (Nagoya,JP), S Yamada (Nagoya,JP), Y Ohkawa (Nagoya,JP), T Suzuki (Toyohashi,JP)

Authors:
M. Ehara1 , K. Shibata2 , M. Kameshima2 , M. Konaka2 , H. Fujiyama2 , M. Kato2 , Y. Higashida2 , A. Shimada2 , S. Yamada3 , Y. Ohkawa4 , T. Suzuki5 , 1Nagoya Heart Center, Cardiology - Nagoya - Japan , 2Nagoya Heart Center, Rehabilitation - Nagoya - Japan , 3Nagoya University Graduate School of Medicine (Health Sciences) - Nagoya - Japan , 4Nagoya Heart Center - Nagoya - Japan , 5Toyohashi Heart Center - Toyohashi - Japan ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 715

Introduction: Impaired chronotropic response (ICR) often affects the recovery of exercise capacity. The purpose of the present study is to investigate whether the persistence of ICR after the completion of phase II cardiac rehabilitation may impact on the future cardiovascular prognosis.

Methods: We enrolled 247 consecutive patients (69 y.o. on average) who participated in phase II cardiac rehabilitation program at least for 3 months (8.5 month on average). All underwent cardiopulmonary exercise test (CPX) at the initial and completion period of rehabilitation. Those who suffered from a life-threatening event within 90 days since rehabilitation started were excluded. Index of heart rate (HR) reserve (HRRI) from CPX data was calculated as the following formula: HRRI = (peak HR - resting HR) / (220 - age - resting HR). Using the established criteria, HRRI <0.80, or 0.62 on beta-blocker regimen, was regarded as “impaired”. Handgrip strength, daily step counts, the left ventricular ejection fraction and blood test data were obtained. The Cox proportional hazards regression analysis was used to assess the independent predictors of the future events. Impaired cases at completion were divided in 2 groups by the median of HRRI (severe and mild), and we finally compared peak HR, HRRI, HR recovery (at 1 minutes after the peak exercise) by CPX between 3 groups (“Normal chronotropic response”, “Mild ICR” and “Severe ICR”). A Kaplan-Meier curve was drawn to compare the incidence of future cardiovascular events.

Results: ICR was detected in 182 cases (74%) at the beginning of rehabilitation, and persisted in 128 (52%) at the completion. Peak HR (median 143 vs. 123 vs. 99/min), HRRI (median 0.895 vs. 0.639 vs. 0.409), HR recovery (median 19 vs. 15 vs. 8/min) were significantly different between groups at the completion (all p<0.001). Peak oxygen consumption had no significant difference. “Severe ICR” group had significantly higher incidence of cardiovascular events than “mild ICR” group (25.0% vs. 7.8%, p=0.008). Multivariate analysis revealed that “severely reduced HRRI” was an independent predictor of future events (hazard ratio 3.1, confident interval: 1.1–8.5). Kaplan-Meier analysis showed significant difference in event-free survival rate between groups (692 days on average, Log Rank p=0.017).

Conclusion: Incidence of cardiac events may partly depend on the severity of ICR at the chronic phase of cardiovascular disease. Persistence of ICR after phase II cardiac rehabilitation can be a prognostic indicator of the future adverse events.

Event-free rate according to ICR

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are